Standout Papers

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patient... 2022 2026 2023 2024248
  1. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. (2022)
    Ghassan K. Abou‐Alfa, Stephen L. Chan et al. Journal of Clinical Oncology

Immediate Impact

2 by Nobel laureates 2 from Science/Nature 61 standout
Sub-graph 1 of 21

Citing Papers

Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
2024 Standout
Precision treatment in advanced hepatocellular carcinoma
2024 Standout
6 intermediate papers

Works of Alejandra Negro being referenced

Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).
2023
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
2022 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Alejandra Negro 482 382 213 32 825
Joerg Trojan 306 313 163 30 914
Koji Miyahara 304 272 175 44 887
Takehiro Hayashi 323 275 123 44 916
Li‐Jian Liang 462 528 129 33 961
A. M. M. Eggermont 537 168 204 25 900
Yu Jin Kim 293 132 318 38 936
Anna Kan 260 333 166 37 863
Richard Létourneau 749 160 274 26 981
Salvatore Lorenzo Renne 197 145 343 44 652
Salvatore Patanè 197 193 140 36 748

All Works

Loading papers...

Rankless by CCL
2026